EP0698015A1
(en)
|
1993-05-14 |
1996-02-28 |
Genentech, Inc. |
Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
|
UA42747C2
(ru)
*
|
1993-12-23 |
2001-11-15 |
Ново Нордіск А/С |
Производные пептида, фармацевтическая композиция и способ стимулирования секреции гормона роста
|
HU221092B1
(en)
*
|
1993-12-23 |
2002-08-28 |
Novo Nordisk As |
Compounds with growth hormone releasing properties
|
US20020111461A1
(en)
*
|
1999-05-21 |
2002-08-15 |
Todd C. Somers |
Low molecular weight peptidomimetic growth hormone secretagogues
|
US5798337A
(en)
*
|
1994-11-16 |
1998-08-25 |
Genentech, Inc. |
Low molecular weight peptidomimetic growth hormone secretagogues
|
HUP9802821A3
(en)
*
|
1995-06-22 |
2000-03-28 |
Novo Nordisk As |
Compounds with growth hormone releasing properties
|
CN1127488C
(zh)
*
|
1996-04-24 |
2003-11-12 |
诺沃挪第克公司 |
具有生长激素释放特性的化合物
|
US6127341A
(en)
*
|
1997-06-20 |
2000-10-03 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
AU7906998A
(en)
|
1997-06-20 |
1999-01-04 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
ZA987383B
(en)
*
|
1997-08-19 |
2000-02-17 |
Lilly Co Eli |
Treatment of congestive heart failure with growth hormone secretagogues.
|
US6329342B1
(en)
|
1997-08-19 |
2001-12-11 |
Eli Lilly And Company |
Treatment of congestive heart failure with growth hormone secretagogues
|
EP1506969B1
(en)
|
1998-01-16 |
2010-06-09 |
Helsinn Therapeutics (U.S.), Inc. |
Compounds with growth hormone releasing properties
|
WO1999039730A1
(fr)
*
|
1998-02-09 |
1999-08-12 |
Kaken Pharmaceutical Co., Ltd. |
Preparation a administration orale contenant des peptides favorisant la secretion d'hormone de croissance
|
US6919315B1
(en)
|
1998-06-30 |
2005-07-19 |
Novo Nordisk A/S |
Compounds with growth hormone releasing properties
|
US6682908B1
(en)
|
1998-07-10 |
2004-01-27 |
Merck & Co., Inc. |
Mouse growth hormone secretagogue receptor
|
CA2333857A1
(en)
|
1998-07-13 |
2000-01-20 |
Merck & Co., Inc. |
Growth hormone secretagogue related receptors and nucleic acids
|
EP1112282A4
(en)
|
1998-08-10 |
2002-10-31 |
Merck & Co Inc |
RECEPTOR OF THE GROWTH HORMONE SECRETION PROMOTER FROM THE DOG
|
AU5671099A
(en)
|
1998-08-14 |
2000-03-06 |
The Administrators Of The Tulane Eductional Fund |
Compounds having growth hormone releasing activity
|
US6639076B1
(en)
|
1998-08-18 |
2003-10-28 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US6696063B1
(en)
|
1998-12-30 |
2004-02-24 |
Applied Research Systems Ars Holding N.V. |
Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
|
US7022677B1
(en)
|
1999-02-18 |
2006-04-04 |
Kaken Pharmaceutical Co., Ltd. |
Amide derivatives as growth hormone secretagogues
|
EP1158996A4
(en)
*
|
1999-02-18 |
2005-01-12 |
Kaken Pharma Co Ltd |
NEW AMID DERIVATIVES AS GROWTH HORMONE SECRETION CONVEYORS
|
US6828331B1
(en)
|
1999-02-19 |
2004-12-07 |
Eli Lilly And Company |
Growth hormone secretagogues
|
US20040192593A1
(en)
*
|
1999-07-26 |
2004-09-30 |
Baylor College Of Medicine |
Protease resistant ti-growth hormone releasing hormone
|
AU772752B2
(en)
|
1999-07-26 |
2004-05-06 |
Baylor College Of Medicine |
Super-active porcine growth hormone releasing hormone analog
|
AU7685200A
(en)
*
|
1999-10-12 |
2001-04-23 |
Kaken Pharmaceutical Co., Ltd. |
Powdery inhalational preparations and process for producing the same
|
UA73530C2
(ru)
|
1999-11-10 |
2005-08-15 |
Ново Нордіск А/С |
Соединение со свойствами освобождения гормона роста
|
JP3498041B2
(ja)
*
|
2000-05-29 |
2004-02-16 |
科研製薬株式会社 |
プラルモレリン含有点鼻用製剤
|
ES2333097T3
(es)
|
2000-05-31 |
2010-02-17 |
Raqualia Pharma Inc |
Uso de secretagogos de la hormona de crecimiento para estimular la motilidad gastrointestinal.
|
US7645898B2
(en)
|
2000-08-24 |
2010-01-12 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and method of use thereof
|
US7919647B2
(en)
|
2000-08-24 |
2011-04-05 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7622503B2
(en)
|
2000-08-24 |
2009-11-24 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators and methods of use thereof
|
US7855229B2
(en)
|
2000-08-24 |
2010-12-21 |
University Of Tennessee Research Foundation |
Treating wasting disorders with selective androgen receptor modulators
|
CA2435563A1
(en)
|
2001-02-02 |
2002-08-15 |
Conjuchem Inc. |
Long lasting growth hormone releasing factor derivatives
|
US7125840B2
(en)
*
|
2001-10-09 |
2006-10-24 |
Eli Lilly And Company |
Substituted dipeptides as growth hormone secretagogues
|
CN100417419C
(zh)
*
|
2001-10-26 |
2008-09-10 |
贝勒医学院 |
改变个体的瘦体重和骨特性的组合物和方法
|
US8853266B2
(en)
|
2001-12-06 |
2014-10-07 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulators for treating diabetes
|
US6831102B2
(en)
|
2001-12-07 |
2004-12-14 |
Bristol-Myers Squibb Company |
Phenyl naphthol ligands for thyroid hormone receptor
|
MY142457A
(en)
|
2001-12-11 |
2010-11-30 |
Advisys Inc |
Plasmid mediated supplementation for treating chronically ill subjects
|
US7015219B2
(en)
|
2001-12-19 |
2006-03-21 |
Bristol-Myers Squibb Company |
3-aryl-hydroxybenzoxazines and 3, 4-dihydro-3-aryl-hydroxybenzoxazines as selective estrogen receptor beta modulators
|
AR038816A1
(es)
*
|
2002-02-07 |
2005-01-26 |
Baylor College Medicine |
Desarrollo modificado de la glandula pituitaria en la progenie de las hembras prenadas tratadas con terapia con la hormona liberadora de la hormona de crecimiento
|
US7772433B2
(en)
|
2002-02-28 |
2010-08-10 |
University Of Tennessee Research Foundation |
SARMS and method of use thereof
|
US7381730B2
(en)
|
2002-03-15 |
2008-06-03 |
Bristol-Myers Squibb Company |
3-arylquinazoline derivatives as selective estrogen receptor beta modulators
|
US20060167268A1
(en)
*
|
2002-04-09 |
2006-07-27 |
Eli Lilly And Company, Patent Division, |
Growth hormone secretagogues
|
ATE338767T1
(de)
*
|
2002-04-09 |
2006-09-15 |
Lilly Co Eli |
Dipeptidische wachstumshormonsekretionsförderern
|
AU2003225305A1
(en)
|
2002-05-08 |
2003-11-11 |
Bristol-Myers Squibb Company |
Pyridine-based thyroid receptor ligands
|
US7405234B2
(en)
|
2002-05-17 |
2008-07-29 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
JP2005539091A
(ja)
|
2002-08-23 |
2005-12-22 |
バラリゼーション−ラシェアシェイ ソサイテ エン コマンディテ |
アテローム性動脈硬化および高コレステロール血症の治療または予防における成長ホルモン放出ペプチド類
|
EP1567487A4
(en)
|
2002-11-15 |
2005-11-16 |
Bristol Myers Squibb Co |
OPEN-CHAINED, PROLYL-FROSTED MODULATORS OF ANDROGEN RECEPTOR FUNCTION
|
US8309603B2
(en)
|
2004-06-07 |
2012-11-13 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
TW200504021A
(en)
|
2003-01-24 |
2005-02-01 |
Bristol Myers Squibb Co |
Substituted anilide ligands for the thyroid receptor
|
WO2004069793A2
(en)
|
2003-01-28 |
2004-08-19 |
Bristol-Myers Squibb Company |
Novel 2-substituted cyclic amines as calcium sensing receptor modulators
|
CA2513743C
(en)
*
|
2003-01-28 |
2013-06-25 |
Advisys, Inc. |
Reducing culling in herd animals growth hormone releasing hormone (ghrh)
|
US7205322B2
(en)
|
2003-02-12 |
2007-04-17 |
Bristol-Myers Squibb Company |
Thiazolidine compounds as calcium sensing receptor modulators
|
US7557143B2
(en)
|
2003-04-18 |
2009-07-07 |
Bristol-Myers Squibb Company |
Thyroid receptor ligands
|
TW200424214A
(en)
*
|
2003-04-21 |
2004-11-16 |
Advisys Inc |
Plasmid mediated GHRH supplementation for renal failures
|
US7265145B2
(en)
|
2003-05-28 |
2007-09-04 |
Bristol-Myers Squibb Company |
Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
|
US7459460B2
(en)
|
2003-05-28 |
2008-12-02 |
Bristol-Myers Squibb Company |
Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators
|
US7476653B2
(en)
|
2003-06-18 |
2009-01-13 |
Tranzyme Pharma, Inc. |
Macrocyclic modulators of the ghrelin receptor
|
US7361642B2
(en)
*
|
2003-08-04 |
2008-04-22 |
Vgx Pharmaceuticals, Inc. |
Canine specific growth hormone releasing hormone
|
AU2003272814A1
(en)
|
2003-10-02 |
2005-05-19 |
Ibrahim Al-Habdan |
Peptide for promoting healing of fractures
|
EP1711187B1
(en)
|
2003-12-31 |
2010-05-12 |
VGX Pharmaceuticals, LLC |
Reducing arthritis and lameness in subjects by growth hormone releasing hormone (ghrh) supplementation
|
ATE507239T1
(de)
*
|
2004-01-20 |
2011-05-15 |
VGX Pharmaceuticals LLC |
Erhöhte sekretion/retention von wachstumshormonfreisetzendem hormon (ghrh) aus muskelzellen durch speziesspezifisches signalpeptid
|
US20050164952A1
(en)
*
|
2004-01-23 |
2005-07-28 |
Vital Pharmaceuticals, Inc. |
Delivery system for growth hormone releasing peptides
|
US7820702B2
(en)
|
2004-02-04 |
2010-10-26 |
Bristol-Myers Squibb Company |
Sulfonylpyrrolidine modulators of androgen receptor function and method
|
US7378426B2
(en)
|
2004-03-01 |
2008-05-27 |
Bristol-Myers Squibb Company |
Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
|
US7625923B2
(en)
|
2004-03-04 |
2009-12-01 |
Bristol-Myers Squibb Company |
Bicyclic modulators of androgen receptor function
|
US7696241B2
(en)
|
2004-03-04 |
2010-04-13 |
Bristol-Myers Squibb Company |
Bicyclic compounds as modulators of androgen receptor function and method
|
US9884038B2
(en)
|
2004-06-07 |
2018-02-06 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator and methods of use thereof
|
US9889110B2
(en)
|
2004-06-07 |
2018-02-13 |
University Of Tennessee Research Foundation |
Selective androgen receptor modulator for treating hormone-related conditions
|
NZ553274A
(en)
*
|
2004-07-23 |
2010-02-26 |
VGX Pharmaceuticals LLC |
Growth hormone releasing hormone enhances the immune response induced by vaccination
|
AU2005277389A1
(en)
|
2004-08-18 |
2006-03-02 |
Elixir Pharmaceuticals, Inc. |
Growth-hormone secretagogues
|
WO2006116401A1
(en)
|
2005-04-28 |
2006-11-02 |
Bristol-Myers Squibb Company |
C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
|
AU2006285026B2
(en)
|
2005-08-31 |
2012-08-09 |
University Of Tennessee Research Foundation |
Treating renal disease, burns, wounds and spinal cord injury with selective androgen receptor modulators
|
CU23558A1
(es)
|
2006-02-28 |
2010-07-20 |
Ct Ingenieria Genetica Biotech |
Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
|
US8058253B2
(en)
*
|
2006-07-06 |
2011-11-15 |
Vgx Pharmaceuticals, Inc. |
Growth hormone releasing hormone treatment to decrease cholesterol levels
|
PT2038252T
(pt)
|
2006-07-12 |
2016-12-16 |
Univ Tennessee Res Found |
Acilanilidos substituidos e métodos de utilização dos mesmos
|
US8299248B2
(en)
|
2006-08-02 |
2012-10-30 |
Cytokinetics, Incorporated |
Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
|
EP2995619B1
(en)
|
2006-08-02 |
2019-09-25 |
Cytokinetics, Inc. |
Certain chemical entities comprising imidazopyrimidines, compositions and methods
|
US9730908B2
(en)
|
2006-08-24 |
2017-08-15 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
PL2054049T3
(pl)
|
2006-08-24 |
2016-11-30 |
|
Podstawione acyloanilidy i sposoby ich stosowania
|
US10010521B2
(en)
|
2006-08-24 |
2018-07-03 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
US9844528B2
(en)
|
2006-08-24 |
2017-12-19 |
University Of Tennessee Research Foundation |
SARMs and method of use thereof
|
BRPI0807046A2
(pt)
|
2007-02-09 |
2015-05-26 |
Tranzyme Pharma Inc |
Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit.
|
US20100099640A1
(en)
|
2007-05-04 |
2010-04-22 |
Joannes Geuns |
Tissue degeneration protection
|
US7968603B2
(en)
|
2007-09-11 |
2011-06-28 |
University Of Tennessee Research Foundation |
Solid forms of selective androgen receptor modulators
|
WO2009155481A1
(en)
|
2008-06-20 |
2009-12-23 |
Gtx, Inc. |
Metabolites of selective androgen receptor modulators and methods of use thereof
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
WO2011133920A1
(en)
|
2010-04-23 |
2011-10-27 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
WO2013190520A2
(en)
|
2012-06-22 |
2013-12-27 |
The General Hospital Corporation |
Gh-releasing agents in the treatment of vascular stenosis and associated conditions
|
US9744149B2
(en)
|
2012-07-13 |
2017-08-29 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US10314807B2
(en)
|
2012-07-13 |
2019-06-11 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
US9622992B2
(en)
|
2012-07-13 |
2017-04-18 |
Gtx, Inc. |
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
|
US9969683B2
(en)
|
2012-07-13 |
2018-05-15 |
Gtx, Inc. |
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
|
US10987334B2
(en)
|
2012-07-13 |
2021-04-27 |
University Of Tennessee Research Foundation |
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
|
US10258596B2
(en)
|
2012-07-13 |
2019-04-16 |
Gtx, Inc. |
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
|
MX2015000572A
(es)
|
2012-07-13 |
2015-09-23 |
Gtx Inc |
Metodo para tratar canceres de mama positivos a receptor de androgeno (ar) con modulador de receptor de androgeno selectivo (sarms).
|
BR112015009107A2
(pt)
|
2012-10-24 |
2017-11-14 |
Daiichi Sankyo Co Ltd |
agente terapêutico para esclerose lateral amiotrófica, uso de um agonista do receptor do secretagogo do hormônio do crescimento ou um sal farmaceuticamente aceitável do mesmo, e, agonista do receptor do secretagogo do hormônio do crescimento ou sal farmaceuticamente aceitável do mesmo
|
US10092627B2
(en)
|
2013-04-08 |
2018-10-09 |
President And Fellows Of Harvard College |
Methods and compositions for rejuvenating skeletal muscle stem cells
|
US9119832B2
(en)
|
2014-02-05 |
2015-09-01 |
The Regents Of The University Of California |
Methods of treating mild brain injury
|
US10328082B2
(en)
|
2014-05-30 |
2019-06-25 |
Pfizer Inc. |
Methods of use and combinations
|
WO2017075535A1
(en)
|
2015-10-28 |
2017-05-04 |
Oxeia Biopharmaceuticals, Inc. |
Methods of treating neurodegenerative conditions
|
MA56396A
(fr)
|
2019-06-27 |
2022-05-04 |
Cytokinetics Inc |
Polymorphes de 1-(2-((((trans)-3-fluoro-1-(3-fluoropyridin-2-yl)cyclobutyl)méthyl)amino)pyrimidin-5-yl)-1h-pyrrole-3-carboxamide
|
WO2023275715A1
(en)
|
2021-06-30 |
2023-01-05 |
Pfizer Inc. |
Metabolites of selective androgen receptor modulators
|